To the full analysis
Buyback calculator for SK Biopharmaceuticals
SK Biopharmaceuticals stock: key metrics
326030.KSSK Biopharmaceuticals had an operating margin of 28.9% and a return on invested capital (ROIC) of 40.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2011 | 27.2% | −64.6% | −51.7% |
| 2012 | 27.3% | −69.5% | −58.6% |
| 2013 | 26.6% | −73.0% | −67.8% |
| 2014 | 35.7% | −54.2% | −51.1% |
| 2015 | 36.0% | −55.2% | −39.3% |
| 2016 | 12.3% | −64.1% | −33.8% |
| 2017 | 4.2% | −114.8% | −114.5% |
| 2018 | no data | no data | no data |
| 2019 | 99.6% | −64.0% | −57.7% |
| 2020 | 92.4% | −921.2% | −951.6% |
| 2021 | 94.7% | 22.7% | 15.5% |
| 2022 | 84.7% | −53.2% | −56.6% |
| 2023 | 90.4% | −5.8% | −9.3% |
| 2024 | 92.1% | 17.6% | 44.0% |
| 2025 | 92.2% | 28.9% | 37.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2011 | −9.0% | −22.5% | −8.4% |
| 2012 | −16.4% | −36.8% | −14.6% |
| 2013 | −27.4% | −47.6% | −24.0% |
| 2014 | −17.1% | −38.7% | −15.5% |
| 2015 | −15.6% | −42.2% | −13.4% |
| 2016 | −20.6% | −27.1% | −15.7% |
| 2017 | −100.0% | −76.0% | −99.3% |
| 2018 | −100.0% | no data | −100.0% |
| 2019 | 200.0% | −79.3% | −51.4% |
| 2020 | −65.3% | −72.3% | −49.5% |
| 2021 | 14.6% | 127.9% | 10.1% |
| 2022 | −44.0% | −70.8% | −21.0% |
| 2023 | −11.6% | −7.7% | −4.5% |
| 2024 | 44.1% | 27.8% | 23.2% |
| 2025 | 32.8% | 40.8% | 22.3% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₩1,334.10)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.